Julia A. Haller - 11 Aug 2022 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
Director
Signature
/s/ Lawrence Kenyon, Attorney-in-Fact
Issuer symbol
OTLK
Transactions as of
11 Aug 2022
Net transactions value
$0
Form type
4
Filing time
15 Aug 2022, 17:16:57 UTC
Previous filing
05 Jul 2022
Next filing
04 Oct 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLK Stock Option (Right to Buy) Award $0 +25,000 $0.000000 25,000 11 Aug 2022 Common Stock 25,000 $1.15 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in three equal installments on each of August 11, 2023, August 11, 2024 and August 11, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.